Homepage Top Section2

The companies will collaborate on the development of GLIX1 as a potential treatment for both newly diagnosed and recurrent GBM. This molecule functions by enhancing TET2 activity within

The submission draws on findings from the TEMPO clinical development programme, which assessed the tolerability, efficacy, and safety of tavapadon in various populations with Parkinson’s disease. This programme

Tremfya is a fully-human, dual-acting monoclonal antibody that works by selectively targeting IL-23, a protein involved in abnormal immune activity. The drug is already approved in the US

ThecaFlex DRx is an investigational implantable device to deliver antisense oligonucleotides (ASOs) intrathecally. The device administers medicines to patients with neurologic disorders. It is designed to offer an

This authorisation is specifically for patients who have symptomatic TGCT, with significant physical functional decline, and for whom surgical intervention is either not an option or would lead

The investment round was jointly spearheaded by Qiming Venture Partners USA and Versant Ventures. It also saw contributions from SV Health Investors, the company’s founding investor, and new

Phase II study of BW-40202, a small interfering RNA (siRNA) therapy targeting complement factor B (CFB), is planned to commence in January 2026. The therapy is also being

The funds will help YolTech in advancing its clinical programmes and global strategic execution. Established in 2021, YolTech Therapeutics is stated to be advancing next-generation in vivo gene-editing

The company aims to achieve early clinical proof-of-concept for the therapy by late 2026. Dewpoint noted that the financing will also expedite the development of its first-in-class c-mod